X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (84) 84
index medicus (72) 72
bortezomib (62) 62
aged (61) 61
female (56) 56
male (56) 56
middle aged (53) 53
human necessities (51) 51
hygiene (51) 51
medical or veterinary science (51) 51
preparations for medical, dental, or toilet purposes (51) 51
multiple myeloma - drug therapy (45) 45
adult (44) 44
hematology (43) 43
multiple myeloma (40) 40
specific therapeutic activity of chemical compounds ormedicinal preparations (37) 37
oncology (36) 36
aged, 80 and over (33) 33
boronic acids - administration & dosage (33) 33
pyrazines - administration & dosage (33) 33
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
treatment outcome (28) 28
dexamethasone (21) 21
therapy (21) 21
multiple myeloma - mortality (20) 20
stem-cell transplantation (20) 20
antineoplastic agents - therapeutic use (18) 18
disease-free survival (17) 17
prednisone - administration & dosage (17) 17
beer (16) 16
biochemistry (16) 16
boronic acids - adverse effects (16) 16
chemistry (16) 16
compositions or test papers therefor (16) 16
condition-responsive control in microbiological orenzymological processes (16) 16
enzymology (16) 16
measuring or testing processes involving enzymes, nucleicacids or microorganisms (16) 16
melphalan - administration & dosage (16) 16
metallurgy (16) 16
microbiology (16) 16
multiple-myeloma (16) 16
mutation or genetic engineering (16) 16
processes of preparing such compositions (16) 16
pyrazines - adverse effects (16) 16
spirits (16) 16
vinegar (16) 16
wine (16) 16
kaplan-meier estimate (15) 15
thalidomide (15) 15
analysis (14) 14
antineoplastic combined chemotherapy protocols - administration & dosage (14) 14
antineoplastic combined chemotherapy protocols - adverse effects (14) 14
care and treatment (14) 14
follow-up studies (14) 14
multiple myeloma - pathology (14) 14
abridged index medicus (13) 13
boronic acids - therapeutic use (13) 13
cancer (13) 13
chemotherapy (13) 13
prednisone (13) 13
pyrazines - therapeutic use (13) 13
recurrence (13) 13
survival (13) 13
trial (13) 13
antineoplastic agents - adverse effects (12) 12
drug administration schedule (12) 12
animals (11) 11
antineoplastic agents - administration & dosage (11) 11
clinical trials (11) 11
dexamethasone - administration & dosage (11) 11
hemic and lymphatic diseases (11) 11
interleukin-6 (11) 11
pharmacology & pharmacy (11) 11
prognosis (11) 11
survival rate (11) 11
combination (10) 10
lenalidomide (10) 10
peripheral neuropathy (10) 10
survival analysis (10) 10
young adult (10) 10
melphalan (9) 9
patients (9) 9
remission induction (9) 9
thalidomide - administration & dosage (9) 9
time factors (9) 9
antibodies, monoclonal - adverse effects (8) 8
cyclophosphamide (8) 8
immune system diseases (8) 8
medicine & public health (8) 8
multiple myeloma - therapy (8) 8
neoplasm staging (8) 8
pharmacokinetics (8) 8
siltuximab (8) 8
transplantation (8) 8
tumor cells, cultured (8) 8
antibodies, monoclonal - administration & dosage (7) 7
antibodies, monoclonal - therapeutic use (7) 7
corticosteroids (7) 7
dose-response relationship, drug (7) 7
double-blind method (7) 7
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (223) 223
French (18) 18
German (9) 9
Portuguese (4) 4
Spanish (4) 4
Croatian (3) 3
Danish (3) 3
Greek (3) 3
Slovenian (3) 3
Chinese (2) 2
Hungarian (2) 2
Norwegian (2) 2
Italian (1) 1
Lithuanian (1) 1
Polish (1) 1
Russian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 17, pp. 1621 - 1634
The addition of the oral proteasome inhibitor ixazomib to a regimen of lenalidomide plus dexamethasone led to a significant prolongation of progression-free... 
SUPERIORITY | MEDICINE, GENERAL & INTERNAL | CARFILZOMIB | RANDOMIZED PHASE-3 | THERAPY | PROTEASOME INHIBITOR MLN9708 | QUALITY-OF-LIFE | BORTEZOMIB | THALIDOMIDE | ANTITUMOR-ACTIVITY | TRANSPLANTATION | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Boron Compounds - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Exanthema - chemically induced | Aged, 80 and over | Adult | Glycine - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Administration, Oral | Kaplan-Meier Estimate | Proportional Hazards Models | Thrombocytopenia - chemically induced | Thalidomide - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Boron Compounds - adverse effects | Aged | Care and treatment | Dosage and administration | Dexamethasone | Multiple myeloma | Thrombocytopenia | Inhibitor drugs | Risk groups | Drug therapy | Peripheral neuropathy | Survival | Patients | Drug dosages | Proteasome inhibitors | Quality of life | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 431 - 440
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 966 - 974
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2015, Volume 372, Issue 10, pp. 944 - 953
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2012, Volume 30, Issue 24, pp. 2946 - 2955
Journal Article
American Journal of Hematology, ISSN 0361-8609, 01/2015, Volume 90, Issue 1, pp. 42 - 49
Journal Article
Journal Article